AcelRx valuation sheet - click here to download.
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) stock recently jumped after a positive Adcom. ACRX now shows over 95 percent improvement this year so far. However, a number of key people have questioned the addition potential of this highly potent drug. While evaluating the company below, we have taken a bigger discount factor to account for the risk this controversy has created.
Dsuvia Controversy & Valuation
AcelRx is developing Dsuvia in collaboration with the Department of Defence as a non-invasive, rapid acting alternative to IV opioids. The drug